The Global Onychomycosis Market size is expected to reach $4.5 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.
A fungal infection of nailscalled onychomycosis results in thickening and discoloration of the nail plate.In general, the word onychomycosiscovers infections caused by yeasts, saprophytic molds, and dermatophytes in addition to dermatophytes.Though fingernails, as well as toenails, can get infected, toenail onychomycosis is more common. Recent studies have shown that mixed infections and infectionsbrought on by non-dermatophyte molds (NDMs) are more common, particularly in warmer climates.
The dermatophyte-induced onychomycosis condition isknown as tinea unguium.Subtypes of onychomycosis are categorized according to the invasion pattern. The most prevalent form of onychomycosis, known as distal subungual onychomycosis (DSO), happens when the fungus colonizes the distal portion of the nail plate. Fungi infiltrate the nail plate's outermost layers in superficial white onychomycosis (SWO).
The organism that causes proximal subungual onychomycosis (PSO) first invades from the underside of the proximal nail fold, thenthe infection subsequently spreads distally. Additionally,Endonyx onychomycosis (EO) refers to the nail plate's fungalinvasion that does not involve nail bed infection. Total dystrophic onychomycosis (TDO), which may follow any other subtypes, is the final stage of onychomycosis. Clinically resembling both the non-fungal and fungal nail disorders, secondary onychomycosis (SO) refers to thenon-fungal nail condition (that is, psoriasis) alongwith a secondary fungal infection.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
A fungal infection of nailscalled onychomycosis results in thickening and discoloration of the nail plate.In general, the word onychomycosiscovers infections caused by yeasts, saprophytic molds, and dermatophytes in addition to dermatophytes.Though fingernails, as well as toenails, can get infected, toenail onychomycosis is more common. Recent studies have shown that mixed infections and infectionsbrought on by non-dermatophyte molds (NDMs) are more common, particularly in warmer climates.
The dermatophyte-induced onychomycosis condition isknown as tinea unguium.Subtypes of onychomycosis are categorized according to the invasion pattern. The most prevalent form of onychomycosis, known as distal subungual onychomycosis (DSO), happens when the fungus colonizes the distal portion of the nail plate. Fungi infiltrate the nail plate's outermost layers in superficial white onychomycosis (SWO).
The organism that causes proximal subungual onychomycosis (PSO) first invades from the underside of the proximal nail fold, thenthe infection subsequently spreads distally. Additionally,Endonyx onychomycosis (EO) refers to the nail plate's fungalinvasion that does not involve nail bed infection. Total dystrophic onychomycosis (TDO), which may follow any other subtypes, is the final stage of onychomycosis. Clinically resembling both the non-fungal and fungal nail disorders, secondary onychomycosis (SO) refers to thenon-fungal nail condition (that is, psoriasis) alongwith a secondary fungal infection.
COVID-19 Impact Analysis
As many hospital institutions and primary care clinics switched their attention to COVID-19 patients, the pandemic led to a decline in diagnoses and had an impact on the sales of medications and other onychomycosis treatment options. In addition, COVID-19 also affected the immunity of people, which increased the chances for acquiring fungal diseases like onychomycosis. The risk of recurrence also multiplied for people who already had the infection. Therefore, the pandemic had an adverse impact on the onychomycosis market.Market Growth Factors
Rising research and development of potential candidates in the pipeline
The rising prevalence of onychomycosis coupled with a lack of viable treatments have increased the demand for better medication. Many of the topical medications on the market cannot reach the depths of the nail bed, making it impossible to entirely heal the infection. As a result, many businesses are trying hard to find compounds that penetrate the nails deeper to overcome this difficulty. Numerous businesses are actively developing new treatments, including BB2603 (Blueberry Therapeutics), Hallux Terbinafine Subungual Gel, and MOB-015 (Moberg Pharma).Growing prevalence of dermatophytic onychomycosis
Onychomycosis' increasing incidence is one of the major factors propelling the market's expansion. Infection of the toenail onychomycosis is far more common than that of the fingernails. The rising prevalence of dermatophyte-caused nail fungal infections and a large rise in the number of prescriptions are propelling the demand for onychomycosis treatment. A significant number of the world's population has onychomycosis, with millions suffering from nail fungus. A further factor contributing to the rise in dermatophytic infection is the rising incidence of diabetes. Hence, in the coming years, all these factors will expedite the need for onychomycosis treatment, which would benefit the market.Market Restraining Factor
Low demand elasticity and non-life-threatening condition
The non-life-threatening characteristics of dermatophytic onychomycosis and the treatment's poor efficacy have also led to intense competition from ineffective alternative treatment methods. For instance, tea tree oil is a substitute product that is increasingly utilized to treat nail infections. Since the current medications licensed for the treatment option of onychomycosis have the potential for significant side effects, liver screening and monitoring are necessary. Therefore, the lower demand for the treatment have the potential to hamper the expansion of the market.Type Outlook
Based on type, the onychomycosis market is categorized into distal subungual, white superficial, proximal subungual, and others. The distal subungual segment garnered the highest revenue share in the onychomycosis market in 2021. The segment's dominance is linked to the FDA's clearance of more generic drugs due to rising demand and rising generic prevalence. Additionally, there are more pharmaceuticals in the pipeline to address the increased demand for effective medications. The most typical kind of onychomycosis is distal subungual. In this, the onycholytic area's proximal edge is ragged, and yellow-white spikes protrude into the nail plate.
Treatment Outlook
On the basis of treatment, the onychomycosis market is divided into oral, topical, and others. The oral segment recorded a significant revenue share in the onychomycosis market in 2021. The segment is growing since oral medications have greater treatment cure rates as well as shorter treatment periods than other forms of antifungals. For example, terbinafine hydrochloride oral medication is the most used treatment for onychomycosis. Additionally, to combat the rising incidence of onychomycosis, some generic drug makers are introducing oral medicines. Theophylline extended-release (ER) tablets, for example, were approved by the U.S. FDA in June 2021.Regional Outlook
Based on region, the onychomycosis market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment witnessed the maximum revenue share in the onychomycosis market in 2021. Onychomycosis's increased frequency in the region as well as helpful government policies can be attributed to the growth. Among the developed nations, North America has one of the highest per capita healthcare costs. Additionally, many people in North America have onychomycosis. The rising incidence rate is increasing the need for effective onychomycosis treatments in the fight against the disease. Due to this, American businesses have made large expenditures in the creation of these medications.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Scope of the Study
By Type
- Distal Subungual
- Proximal Subungual
- White Superficial
- Others
By Treatment
- Topical
- Oral
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Australia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Onychomycosis Market, by Type
1.4.2 Global Onychomycosis Market, by Treatment
1.4.3 Global Onychomycosis Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Onychomycosis Market by Type
3.1 Global Distal Subungual Market by Region
3.2 Global Proximal Subungual Market by Region
3.3 Global White Superficial Market by Region
3.4 Global Others Market by Region
Chapter 4. Global Onychomycosis Market by Treatment
4.1 Global Topical Market by Region
4.2 Global Oral Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Onychomycosis Market by Region
5.1 North America Onychomycosis Market
5.1.1 North America Onychomycosis Market by Type
5.1.1.1 North America Distal Subungual Market by Country
5.1.1.2 North America Proximal Subungual Market by Country
5.1.1.3 North America White Superficial Market by Country
5.1.1.4 North America Others Market by Country
5.1.2 North America Onychomycosis Market by Treatment
5.1.2.1 North America Topical Market by Country
5.1.2.2 North America Oral Market by Country
5.1.2.3 North America Others Market by Country
5.1.3 North America Onychomycosis Market by Country
5.1.3.1 US Onychomycosis Market
5.1.3.1.1 US Onychomycosis Market by Type
5.1.3.1.2 US Onychomycosis Market by Treatment
5.1.3.2 Canada Onychomycosis Market
5.1.3.2.1 Canada Onychomycosis Market by Type
5.1.3.2.2 Canada Onychomycosis Market by Treatment
5.1.3.3 Mexico Onychomycosis Market
5.1.3.3.1 Mexico Onychomycosis Market by Type
5.1.3.3.2 Mexico Onychomycosis Market by Treatment
5.1.3.4 Rest of North America Onychomycosis Market
5.1.3.4.1 Rest of North America Onychomycosis Market by Type
5.1.3.4.2 Rest of North America Onychomycosis Market by Treatment
5.2 Europe Onychomycosis Market
5.2.1 Europe Onychomycosis Market by Type
5.2.1.1 Europe Distal Subungual Market by Country
5.2.1.2 Europe Proximal Subungual Market by Country
5.2.1.3 Europe White Superficial Market by Country
5.2.1.4 Europe Others Market by Country
5.2.2 Europe Onychomycosis Market by Treatment
5.2.2.1 Europe Topical Market by Country
5.2.2.2 Europe Oral Market by Country
5.2.2.3 Europe Others Market by Country
5.2.3 Europe Onychomycosis Market by Country
5.2.3.1 Germany Onychomycosis Market
5.2.3.1.1 Germany Onychomycosis Market by Type
5.2.3.1.2 Germany Onychomycosis Market by Treatment
5.2.3.2 UK Onychomycosis Market
5.2.3.2.1 UK Onychomycosis Market by Type
5.2.3.2.2 UK Onychomycosis Market by Treatment
5.2.3.3 France Onychomycosis Market
5.2.3.3.1 France Onychomycosis Market by Type
5.2.3.3.2 France Onychomycosis Market by Treatment
5.2.3.4 Russia Onychomycosis Market
5.2.3.4.1 Russia Onychomycosis Market by Type
5.2.3.4.2 Russia Onychomycosis Market by Treatment
5.2.3.5 Spain Onychomycosis Market
5.2.3.5.1 Spain Onychomycosis Market by Type
5.2.3.5.2 Spain Onychomycosis Market by Treatment
5.2.3.6 Italy Onychomycosis Market
5.2.3.6.1 Italy Onychomycosis Market by Type
5.2.3.6.2 Italy Onychomycosis Market by Treatment
5.2.3.7 Rest of Europe Onychomycosis Market
5.2.3.7.1 Rest of Europe Onychomycosis Market by Type
5.2.3.7.2 Rest of Europe Onychomycosis Market by Treatment
5.3 Asia Pacific Onychomycosis Market
5.3.1 Asia Pacific Onychomycosis Market by Type
5.3.1.1 Asia Pacific Distal Subungual Market by Country
5.3.1.2 Asia Pacific Proximal Subungual Market by Country
5.3.1.3 Asia Pacific White Superficial Market by Country
5.3.1.4 Asia Pacific Others Market by Country
5.3.2 Asia Pacific Onychomycosis Market by Treatment
5.3.2.1 Asia Pacific Topical Market by Country
5.3.2.2 Asia Pacific Oral Market by Country
5.3.2.3 Asia Pacific Others Market by Country
5.3.3 Asia Pacific Onychomycosis Market by Country
5.3.3.1 China Onychomycosis Market
5.3.3.1.1 China Onychomycosis Market by Type
5.3.3.1.2 China Onychomycosis Market by Treatment
5.3.3.2 Japan Onychomycosis Market
5.3.3.2.1 Japan Onychomycosis Market by Type
5.3.3.2.2 Japan Onychomycosis Market by Treatment
5.3.3.3 India Onychomycosis Market
5.3.3.3.1 India Onychomycosis Market by Type
5.3.3.3.2 India Onychomycosis Market by Treatment
5.3.3.4 Australia Onychomycosis Market
5.3.3.4.1 Australia Onychomycosis Market by Type
5.3.3.4.2 Australia Onychomycosis Market by Treatment
5.3.3.5 South Korea Onychomycosis Market
5.3.3.5.1 South Korea Onychomycosis Market by Type
5.3.3.5.2 South Korea Onychomycosis Market by Treatment
5.3.3.6 Singapore Onychomycosis Market
5.3.3.6.1 Singapore Onychomycosis Market by Type
5.3.3.6.2 Singapore Onychomycosis Market by Treatment
5.3.3.7 Rest of Asia Pacific Onychomycosis Market
5.3.3.7.1 Rest of Asia Pacific Onychomycosis Market by Type
5.3.3.7.2 Rest of Asia Pacific Onychomycosis Market by Treatment
5.4 LAMEA Onychomycosis Market
5.4.1 LAMEA Onychomycosis Market by Type
5.4.1.1 LAMEA Distal Subungual Market by Country
5.4.1.2 LAMEA Proximal Subungual Market by Country
5.4.1.3 LAMEA White Superficial Market by Country
5.4.1.4 LAMEA Others Market by Country
5.4.2 LAMEA Onychomycosis Market by Treatment
5.4.2.1 LAMEA Topical Market by Country
5.4.2.2 LAMEA Oral Market by Country
5.4.2.3 LAMEA Others Market by Country
5.4.3 LAMEA Onychomycosis Market by Country
5.4.3.1 Brazil Onychomycosis Market
5.4.3.1.1 Brazil Onychomycosis Market by Type
5.4.3.1.2 Brazil Onychomycosis Market by Treatment
5.4.3.2 Argentina Onychomycosis Market
5.4.3.2.1 Argentina Onychomycosis Market by Type
5.4.3.2.2 Argentina Onychomycosis Market by Treatment
5.4.3.3 UAE Onychomycosis Market
5.4.3.3.1 UAE Onychomycosis Market by Type
5.4.3.3.2 UAE Onychomycosis Market by Treatment
5.4.3.4 Saudi Arabia Onychomycosis Market
5.4.3.4.1 Saudi Arabia Onychomycosis Market by Type
5.4.3.4.2 Saudi Arabia Onychomycosis Market by Treatment
5.4.3.5 South Africa Onychomycosis Market
5.4.3.5.1 South Africa Onychomycosis Market by Type
5.4.3.5.2 South Africa Onychomycosis Market by Treatment
5.4.3.6 Nigeria Onychomycosis Market
5.4.3.6.1 Nigeria Onychomycosis Market by Type
5.4.3.6.2 Nigeria Onychomycosis Market by Treatment
5.4.3.7 Rest of LAMEA Onychomycosis Market
5.4.3.7.1 Rest of LAMEA Onychomycosis Market by Type
5.4.3.7.2 Rest of LAMEA Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Companies Mentioned
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Methodology
LOADING...
